Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

• ClinicalTrials.gov Identifier: NCT02824913
• Recruitment Status: Terminated
• First Posted: July 7, 2016
• Results First Posted: January 19, 2018
• Last Update Posted: August 31, 2018
• Sponsor: Parion Sciences
• Information provided by (Responsible Party): Parion Sciences

Study Description

Brief Summary:

The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.

Condition or disease	Intervention/treatment	Phase
Dry Eye Disease	Drug: P-321 Ophthalmic Solution; Drug: P-321 Ophthalmic Solution placebo	Phase 2

Detailed Description:

This is a single-center, randomized, cross-over placebo controlled study to evaluate the changes in tear volume by P-321 Ophthalmic Solution and Placebo. The study will enroll subjects with tear deficient dry eye disease to receive sequentially one of two treatment sequences: P-321 Ophthalmic Solution then Placebo or Placebo then P-321. The study will consist of two Phases: In each Phase, subjects will be treated with P-321 Ophthalmic Solution under the same study design.

Approximately twenty-four eligible subjects will complete the study with approximately 8 subjects participating in Phase 1 and the remainder of the 24 subjects participating in the phase 2. Decisions on the dose to be used in Phase 2 will be made based on Phase 1 data.

The study will consist of three study visits: a Screening Visit (Visit 1), and two treatment visits (Visit 2 and Visit 3). The primary and secondary outcome measures will be assessed at each treatment visit. Safety assessments include adverse events (AEs).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Characterized by Low Tear Volume
• Actual Study Start Date: July 2016
• Actual Primary Completion Date: March 2017
• Actual Study Completion Date: March 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: P-321 Ophthalmic Solution; 0.017% P-321 Ophthalmic Solution will be administered to approximately 8 patients in Phase I and either 0.05% P-321 Ophthalmic Solution or 0.01% P-321 Ophthalmic Solution or additional 0.017% P-321 Ophthalmic Solution will be administered to approximately 16 patients in Phase II	Drug: P-321 Ophthalmic Solution; Other Name: P-321
Placebo Comparator: Drug: P-321 Ophthalmic Solution placebo; Placebo treatment administered to approximately 8 patients in Phase I and approximately 16 patients in Phase II	Drug: P-321 Ophthalmic Solution placebo; Other Names: Placebo Comparator; Placebo

Outcome Measures

Primary Outcome Measures :

1. Change in Total Tear Meniscus Volume Following the Administration of P-321 Ophthalmic Solution or Placebo [ Time Frame: Pre-dose and up to six hours after dose ]
   Tear meniscus volume, from measurements of tear meniscus area by UHR-OCT and the length of the eyelid was estimated over time (0 to 6 hours) following administration of placebo or P-321 Ophthalmic Solution.

Secondary Outcome Measures :

1. Lower Tear Meniscus Height as Measured by the Keratograph 5M [ Time Frame: Pre-dose and up to six hours after dose ]
   Tear meniscus height of the inferior eyelid was measured with the Keratograph 5M over time (0 to 6 hours) following the administration of placebo or P-321 Ophthalmic Solution
2. Comparison of Lower Tear Meniscus Height Measurements Between UHR-OCT and Keratograph 5M [ Time Frame: Pre-dose and up to six hours after dose ]
   Tear meniscus height of the inferior eyelid was measured by UHR-OCT and Keratograph 5M over time (0 to 6 hours) following the administration of placebo or P-321 Ophthalmic Solution
3. Adverse Events [ Time Frame: 2 or 7 hours ]
   Number of patients experiencing adverse events comparing P-321 to placebo

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Provide written informed consent
2. Male or female subjects aged 18 to 80 years
3. Have a history of predominantly tear-deficient dry eye of mild to moderate severity, supported by a previous clinical diagnosis
4. Have normal lid anatomy

5. Subjects must:

   1. Remain on current medications for the duration of the study and have been on the current medication regimen at least during the past 28 days

Exclusion Criteria:

1. Have undergone refractive eye surgery in either eye during the past 12 months
2. Have undergone uncomplicated cataract surgery in either eye during the past 3 months
3. Have undergone previous eyelid surgery in either eye (External blepharoplasty, not resulting in exposure or abnormal blinking is allowed)
4. Have undergone botulinum toxin (BotoxTh1 or equivalent) injection in the periocular area within 3 months prior to Visit 1
5. Subjects that have a systemic, multi-organ disease requiring active medical or surgical treatment are excluded with the exception of subjects with SS or GVHD
6. Have punctal plugs, punctal occlusion, history of nasolacrimal duct obstruction or wear scleral lens.
7. Past or present exposure keratopathy, neurotrophic keratopathy, lagophthalmos, or trichiasis

Contacts and Locations

Locations

United States, Florida

Bascom Palmer Eye Institute, University of Miami Health System

Plantation, Florida, United States, 33324

Sponsors and Collaborators

Parion Sciences

Investigators

• Study Director: Jose Boyer; Parion Sciences

  Study Documents (Full-Text)

Documents provided by Parion Sciences:

Study Protocol and Statistical Analysis Plan  [PDF] September 7, 2017

More Information

• Responsible Party: Parion Sciences
• ClinicalTrials.gov Identifier: NCT02824913
• Other Study ID Numbers: P-321-201
• First Posted: July 7, 2016
• Results First Posted: January 19, 2018
• Last Update Posted: August 31, 2018
• Last Verified: December 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Dry Eye Syndromes; Keratoconjunctivitis Sicca; Eye Diseases; Lacrimal Apparatus Diseases; Keratoconjunctivitis; Conjunctivitis; Conjunctival Diseases; Keratitis; Corneal Diseases; Pharmaceutical Solutions; Ophthalmic Solutions